Centre de Recherche en Cancérologie de Marseille, INSERM UMR U891, Marseille, France.
J Clin Invest. 2011 Sep;121(9):3609-22. doi: 10.1172/JCI45816. Epub 2011 Aug 15.
NK cells are a major component of the antitumor immune response and are involved in controlling tumor progression and metastases in animal models. Here, we show that dysfunction of these cells accompanies human breast tumor progression. We characterized human peripheral blood NK (p-NK) cells and malignant mammary tumor-infiltrating NK (Ti-NK) cells from patients with noninvasive and invasive breast cancers. NK cells isolated from the peripheral blood of healthy donors and normal breast tissue were used as controls. With disease progression, we found that expression of activating NK cell receptors (such as NKp30, NKG2D, DNAM-1, and CD16) decreased while expression of inhibitory receptors (such as NKG2A) increased and that this correlated with decreased NK cell function, most notably cytotoxicity. Importantly, Ti-NK cells had more pronounced impairment of their cytotoxic potential than p-NK cells. We also identified several stroma-derived factors, including TGF-β1, involved in tumor-induced reduction of normal NK cell function. Our data therefore show that breast tumor progression involves NK cell dysfunction and that breast tumors model their environment to evade NK cell antitumor immunity. This highlights the importance of developing future therapies able to restore NK cell cytotoxicity to limit/prevent tumor escape from antitumor immunity.
自然杀伤 (NK) 细胞是抗肿瘤免疫反应的主要组成部分,参与控制动物模型中的肿瘤进展和转移。在这里,我们表明这些细胞的功能障碍伴随着人类乳腺癌的进展。我们从患有非浸润性和浸润性乳腺癌的患者中表征了外周血 NK(p-NK)细胞和恶性乳腺肿瘤浸润 NK(Ti-NK)细胞。从健康供体的外周血和正常乳腺组织中分离的 NK 细胞用作对照。随着疾病的进展,我们发现激活 NK 细胞受体(如 NKp30、NKG2D、DNAM-1 和 CD16)的表达减少,而抑制性受体(如 NKG2A)的表达增加,这与 NK 细胞功能下降有关,尤其是细胞毒性。重要的是,Ti-NK 细胞的细胞毒性潜力受损比 p-NK 细胞更为明显。我们还鉴定了几种基质衍生的因子,包括 TGF-β1,这些因子参与了肿瘤诱导的正常 NK 细胞功能下降。因此,我们的数据表明,乳腺癌进展涉及 NK 细胞功能障碍,并且乳腺肿瘤模拟其环境以逃避 NK 细胞的抗肿瘤免疫。这突出了开发能够恢复 NK 细胞细胞毒性以限制/预防肿瘤逃避抗肿瘤免疫的未来疗法的重要性。